Noninvasive assessment of disease activity in patients with nonalcoholic fatty liver disease (NAFLD) and alcoholic liver disease (ALD) is still unsettled, but essential for the evaluation of disease progression. We here studied the association of total (M65) and caspase-cleaved (M30) serum keratin-18 fragments (n 5 204) with histological parameters (n 5 106) in heavy drinkers primarily admitted for alcohol withdrawal before and after alcohol detoxification. An age-, sex-, and fibrosis-stage matched NAFLD cohort (n 5 30) was used for comparison. The prognostic value of M30 and M65 levels were assessed in an additional prospectively followed-up cohort of 230 patients with alcoholic cirrhosis (AC) using competing risk analyses. Among the histological parameters, both M30/65 correlated significantly and better than any other serum marker with apoptosis and liver damage, such as ballooning (r 5 0.65; P < 0.001), followed by lobular inflammation (0.48; P < 0.001), steatosis (0.46; P < 0.001), but less with fibrosis (0.24; P < 0.001). Area under the receiver operating characteristics curves to detect ballooning, steatosis, or steatohepatitis (SH) were slightly better for M30 (P < 0.005). Optimal M30 cut-off values for mild and severe ballooning were 330 and 420 U/L, and 290 and 330 U/L for SH grades 1 and 2. No significant differences of M30/65 were found between the matched NAFLD and ALD cohort. In contrast to aspartate-amino-transferase and M65, M30 levels increased significantly from 391 to 518 U/L during alcohol detoxification. Moreover, levels of M30 and M65 predicted non-hepatocellular carcinoma liver-related mortality in patients with AC during a mean observation interval of 67.2 months. Conclusion: Our data suggest M30 as highly specific marker of liver apoptosis both in ALD and NAFLD. In addition, hepatocellular apoptosis, as determined by M30 levels, occurs during alcohol withdrawal, and survival data point toward a novel underestimated role of apoptosis in patients with ALD. (HEPATOLOGY 2017;66:96-107).
A lcoholic liver disease (ALD) and nonalcoholic fatty liver disease (NAFLD) are the most common liver diseases worldwide. (1) (2) (3) Although most patients with steatosis tend to have a benign clinical course, a significant proportion of approximately 10%-20% develop cirrhosis and hepatocellular carcinoma (HCC). However, it still remains poorly understood why some patients with simple steatosis in the absence of alcohol progress to steatohepatitis (SH), whereas others do not. Both ALD and NAFLD not only share a similar histology, but they also show common risk factors, such as female sex, obesity, and diabetes, as well as genetic and mechanistic similarities. (4) For instance, for both diseases, polymorphisms in the gene encoding for patatin-like phospholipase 3/adiponutrin have been recently identified as an important genetic risk factor, whereas cytochrome P450 2E1-associated liver damage has been established as an important progression factor. (5) (6) (7) One of the major unresolved clinical issues is the development of early and noninvasive prognostic markers of alcoholic steatohepatitis (ASH)/nonalcoholic steatohepatitis (NASH). Increasing evidence suggests an important role for hepatocyte apoptosis in the progression of ALD and NAFLD, (8, 9) although several other forms of cell death have been described, including necrosis, necroptosis, autophagic cell death, and others. (10) Both apoptosis and necrosis have also been proposed to be responsible for the development and progression of liver fibrosis (LF). (11) Early during apoptosis, caspases are activated and cleave various substrates, including keratin-18 (K18). (12, 13) K18 is a member of the intermediate filament family of cytoskeletal proteins. (14) Together with K8, K18 represents the major intermediate filament protein in liver cells. (15) K18 is important for the maintenance of hepatocyte integrity, given that deficiency of intact K18 results in liver damage and dysfunction. (16, 17) The apoptotic cleavage of K18 exposes two epitopes: M30, a marker of apoptosis (caspase-mediated cleavage), and M65, an epitope exposed to fragmented K18 variants released from dying cells, thus a marker of overall cell death. (12) The caspase-generated cleavage fragments of K18 can be detected in serum by the M30 antibody, which specifically labels early apoptotic, but not necrotic, epithelial cells. (13) Unfortunately, the interpretation of serum keratin levels has been complicated given that they are elevated in a great variety of pathologies. Serum keratin levels are widely used as tumor markers, (14) and they were only later found to be increased in nonmalignant diseases. (18) In fact, M30 and M65 are elevated in various liver diseases, such as hepatitis B virus (HBV), (19) hepatitis C virus (HCV), (20) and ischemia/reperfusion injury following liver transplantation (LT). (21) Several studies have been performed on patients with NAFLD, (22) (23) (24) and M30 has been proposed as a diagnostic and staging marker for NAFLD before bariatric surgery. (25) However, their levels were associated with all stages of liver disease, creating a debate about their specificity namely in acute liver failure (ALF). (26) (27) (28) Elevated K18 levels have also been found in patients with ALD, including the rare, but prognostically unfavorable, alcoholic hepatitis (AH). (29, 30) K18 is the main component of Mallory-Denk bodies (MDB), which are a hallmark of AH. In AH, K8/18 become hyperphosphorylated, which has been suggested to contribute to MDB formation. (29) To better clarify the significance of K18 in ALD, we here studied total (M65) and caspase-cleaved (M30) serum K18 fragments in clinically wellcharacterized heavy drinkers admitted for alcohol detoxification and correlated these with histological findings. A well-matched cohort of NAFLD patients served as a control. In addition, we studied the influence of alcohol detoxification on M65 and M30 serum levels and evaluated their prognostic power with regard to liver-related death. Our data suggest that both markers primarily detect liver apoptosis. They do not differ significantly between matched ALD and NAFLD patients and increase during alcohol withdrawal. We finally show that both M30 and M65 are independent predictors of non-HCC liver-related death in patients with ALD. These findings highlight the role of apoptosis dysregulation in patients with ALD and may be valid for patients with NAFLD.
Patients and Methods

PATIENT COHORTS AND CLINICAL DATA
We studied 234 Caucasian patients (50.4% male; 18-75 years; mean age, 46.5-61.2) with ALD (n 5 204) and NAFLD (n 5 30) that were enrolled at Salem Medical Center Heidelberg and Hannover Medical School, respectively. The study design is shown in Fig. 1 . All patients with ALD were heavy drinkers (>80 g per day in males and >60 g per day in females) with a mean alcohol consumption of 185.8 6 9.5 g/day. Patients' characteristics are given in Table 1 . The study protocol was reviewed and approved by the local ethics committee, and all patients gave written informed consent before inclusion. The natural course of M30 and M65 levels upon alcohol detoxification was studied in 123 patients over a mean detoxification period of 5.3 days. All patients underwent careful clinical examination, standard serological testing (venous blood sampling), abdominal ultrasound (US), and liver stiffness (LS) measurement by transient elastography (TE; FibroScan; Echosens SA, Paris, France), respectively. Hepatic fat content was further assessed with the FibroScan device by measuring the controlled attenuation parameter (CAP). (31) Other causes of liver diseases were ruled out in all patients serologically by screening for antimitochondrial antibody, antinuclear antibody, HBV, and HCV. For a comparative analysis, biopsy-proven patients with NAFLD (n 5 30) that matched for sex, fibrosis stage, and age were included (see Table 2 ). Survival was studied in patients with manifest alcoholic liver cirrhosis (n 5 230) who were consecutively referred to the Jean Verdier Hospital Liver Unit Paris between January 2000 and December 2010. They fulfilled the following inclusion criteria: (1) histologically proven cirrhosis; (2) daily excessive alcohol consumption (>80 g per day in males and >60 g per day in females for at least 10 years); (3) no infection from human immunodeficiency virus, HCV, or HBV; (4) no evidence of HCC at the time of inclusion; (5) residence in France; (6) acceptance of regular followup; (7) Caucasian origin; and (8) availability of serum samples at the time of liver biopsy and written informed consent for use of frozen serum samples. Samples were provided by the CRB (liver disease biobank) Groupe Hospitalier Paris Seine-Saint-Denis BB-0033-00027. The study protocol was in conformity with ethical guidelines of the 1975 Declaration of Helsinki and approved by the local ethics committee. For each patient, date of inclusion was the date of the first liver biopsy. After inclusion, all patients were followed and evaluated at minimum 6-month intervals by physical examination and liver ultrasonography. If these investigations suggested possible HCC, computed tomography, magnetic resonance imaging, and/or guided liver biopsy were performed according to recommendations of the Barcelona Conference. (32) Follow-up ended at the date of death or LT (considered as death) or at the last recorded visit (or information gathering) within the 6 months preceding August 31, 2014. All included patients were followedup for at least 2 years; patients lost during follow-up after this period were included in the analysis and censored at the date of the last recorded information.
LIVER HISTOLOGY AND IMMUNOSTAINING
One hundred six patients with ALD and all 30 with NAFLD were biopsied and scored independently by pathologists from two centers (T.L. and C.L.) who were blinded to the study. Liver specimens (mean biopsy lengths of 16.1 6 12.5 mm) were obtained percutaneously using the Menghini technique under US guidance, fixed in formalin, and embedded in paraffin. For histological analysis, 4-lm sections were dewaxed and stained with hematoxylin and eosin (H&E), Chromotrop-Anilinblue, and Sirius Red using standard procedures. Histological scoring was performed as described by Kleiner et al. (33) Accordingly, steatohepatitis (SH) grade 1 is borderline representing NAFLD activity score (NAS) 3 and 4 and SH grade 2 Data are presented as mean 6 SD or in %. Abbreviations: AP, alkaline phosphatase; Apo-A1, apolipoprotein A1; INR, international normalized ratio; PIIINP, N-terminal propeptide of type III procollagen. is manifest NASH. In addition, fibrosis was assessed using the semiquantitative severity score according to Chevallier et al. (34) Apoptosis was further analyzed by immunohistochemistry (IHC) using antibodies against activated caspase 3 (R&D Systems, Minneapolis, MN) or M30 (Roche, Basel, Switzerland). Hepatocellular ballooning was detected by the loss of cytoplasmic staining with antibodies against the intermediate filament proteins, K8 and K18 (Neomarkers, Fremont, CA) as recently described. (35) The histological diagnosis of SH was based on the minimal criteria of steatosis (any degree), lobular inflammation, and ballooning. (36) 
SEROLOGICAL DETECTION OF CASPASE-CLEAVED (M30), TOTAL (M65) K18 LEVELS, CYTOKINES, AND GROWTH FACTORS
For quantitative measurement of the caspasegenerated neoepitope of K18, we used the M30-Apoptosense enzyme-linked immunosorbent assay (ELISA), according to the manufacturer's instructions (Peviva, Bromma, Sweden) and as described. (37) We further used the M65 and M65 EpiDeath (M65ED) ELISA (Peviva), which quantifies both uncleaved and caspase-cleaved K18. The M65 assay is based on the capture (M6) and detection (M5) antibodies that are directed against two different epitopes of K18 and recognize total K18. Inversely to the M65 ELISA, the M65ED ELISA uses the M6 antibody for detection and the M5 as capture antibody, resulting in improved binding specificity and lower signals in healthy controls. (38) Levels of hepatocyte growth factor (HGF), interleukin-6 (IL-6), tumor necrosis factor alpha (TNFalpha), and epidermal growth factor (EGF) were assessed by ELISA using Quantikine ELISA Kits (#DHG00, #D6050, #DTA00C, and #DEG00) from R&D Systems.
TE AND CAP
LS was measured by TE (FibroScan; Echosens). TE was performed by physicians with at least 12 months of experience in abdominal US and TE on the right lobe of the liver in the intercostal position according to established protocols. (39) Fibrosis stages were determined using recently established algorithms, including the consideration of transaminase levels. (39, 40) CAP was used to noninvasively assess steatosis on the FibroScan platform using the M probe. (31) CAP values are expressed in dB/m and range from 100 to 400 dB/m. In addition, liver size, spleen size, ascites formation, and semiquantitative liver steatosis (0-3) were assessed by abdominal US.
STATISTICAL ANALYSIS
For all assays, a cubic spline algorithm was used for data interpolation. Statistical analyses were performed using Graphpad Prism (version 5.0; GraphPad Software Inc., La Jolla, CA) and SPSS software (version 19.0; SPSS, Inc., Chicago, IL) and confirmed by a biostatistician. All assays were performed in duplicate. Data are presented as means with SEM. Different serum markers in patients and healthy controls were compared using the Mann-Whitney U test. Regression analysis was performed to calculate the Spearman rank-correlation coefficient. Receiver operating characteristics (ROC) analysis was calculated. A multivariate logistic regression analysis was performed in order to adjust for variables found to be associated with fibrosis or NASH. Qualitative variables were compared using Fisher's exact test, the chi-squared test, or the chisquared trend test with one degree of freedom, whereas quantitative variables were compared using the nonparametric Kruskal-Wallis test. The Kaplan-Meier method was used to estimate the occurrence of death for each parameter noted at enrollment. The distribution of death and HCC was compared with the logrank test. A significant level <0.10 was used to select variables for the Cox proportional hazards model using a step-wise procedure with a threshold of a 5 0.05. Variables associated with risk of death or HCC, based on knowledge and findings from previous studies, were also selected for multivariate analyses (age, sex, body mass index [BMI], diabetes, Child-Pugh score, and platelet count). Statistical analyses were performed using the SAS System Package (version 8.02; SAS Institute Inc., Cary, NC). All reported P values are uncorrected and two-tailed. Associations were considered statistically significant at a two-tailed a of 0.05.
Results
M30 AND M65 ARE PRIMARILY MARKERS OF LIVER CELL DAMAGE
M30 and M65 levels have been proposed to be highly associated with the degree of fibrosis and steatosis. We here compared both markers with serum liver tests and a detailed set of histological parameters (Table 2A,B) . The extracted analysis in Table 2A demonstrates that M65 primarily correlates with histological signs of liver damage, such as ballooning (0.65; P < 0.001) and MDB (0.554; P < 0.001), followed by lobular inflammation, steatosis, and last, but not least, fibrosis. Likewise, M30 correlated with histological signs of liver injury followed by steatosis and fibrosis. M65 was more tightly associated with all serum markers of liver injury (Table 2B ). Of note, M65 correlated better with transaminase levels as compared to LS, which reflects both inflammation and fibrosis. (40) (41) (42) The rather weak association with fibrosis was confirmed with other markers of fibrosis, such as serum markers (hyaluronan) or US (not shown). Finally, we determined the association of LF, as determined by semiquantitative severity score, ballooning, inflammation, and steatosis, with other histological and serum parameters (Supporting Table S1 ). Again, the association of M30 and M65 levels was only weakly associated with fibrotic remodeling, whereas highly associated with ballooning, inflammation, and steatosis. ROC analysis (see Supporting Table S2) 
M30 AND M65 HIGHLY CORRELATE WITH HISTOLOGICAL MARKERS OF APOPTOSIS
Because the M30 antibody detects caspase-cleaved cytokeratin-18 fragments, we studied, in more detail, parameters of apoptosis and keratin 8/18 damage (e.g., ballooning) in liver biopsies using IHC for M30, activated caspase 3, and K8/18. Both M30 and M65 levels were highly associated with histological markers of apoptosis and hepatocellular ballooning (Table 2A) . Best association for both markers were found with ballooning in K8/18 stained sections (r 5 0.627; P < 0.001). Importantly, M30 levels in serum were highly associated with M30 staining of damaged hepatocytes (r 5 0.504; P < 0.001), although loss of M30 had been reported recently. (35) To better illustrate spatial expression of M30, Fig. 2 demonstrates morphological and IHC features of SH and M30 expression in both a case of alcoholic fatty liver (AFL) and ASH, together with the corresponding serum levels of M30. In summary, both serum markers excellently reflect histological staining for apoptosis, and, in fact, M30 serum levels are good indicators of the hepatic M30 stains obtained from liver biopsies.
K18-RELATED SERUM MARKERS DO NOT DIFFER SIGNIFICANTLY BETWEEN MATCHED ALD AND NAFLD COHORTS
M30 levels have been intensively discussed as activity and prognostic markers in patients with NAFLD. To better characterize potential differences between ALD and NAFLD patients, we analyzed 30 additional patients with NASH who were matched with a subcohort of our ALD patients with regard to sex, age, and fibrosis stage. There were no significant differences between both cohorts with regard to both serum markers, although they tended to be generally higher in patients with ALD (Supporting Table S3 ). Notably, liver damage, as determined by histology, did not significantly differ between both cohorts. Although BMI and glucose level were slightly higher in NAFLD patients, these did not meet statistical significance. In summary, M30 and M65 levels seem to be comparable between a sex-, age-, and fibrosis-matched ALD and NAFLD cohort.
UNEXPECTED INCREASE OF M30 DURING ALCOHOL DETOXIFICATION
We then analyzed the course of M30 and M65 serum levels in 123 heavy drinkers who underwent alcohol detoxification over a mean interval of 5.3 days. As expected, AST, M65, LS, and also CAP significantly decreased during the alcohol withdrawal time (Fig. 3) . Thus, AST fell by 44% from 71 to 40 U/L, M65 decreased by 27% from 518 to 377 U/L, LS dropped from 12.4 to 10.4 kPa, while CAP changed from 340 to 304 dB/m. To our surprise, however, M30 did not decrease, but significantly increased by 32% from a mean of 391 to 518 U/L during alcohol detoxification. Based on our clinical and serum parameters, no further information could be identified about conditions or factors that modulate the elevation of M30 in response to alcohol withdrawal. To learn more about the potential involvement of important cytokines and growth factors relevant to liver regeneration, we also measured serum levels of TNFalpha, IL-6, HGF, and EGF using ELISA. (43, 44) Whereas TNFalpha and IL-6 did not change significantly in response to alcohol detoxification (see Supporting Fig.  S1 ), a highly significant increase of EGF serum levels was observed (see Fig. 3 ). Notably, no direct association of EGF levels with other serum markers, namely with M30, were observed. HGF slightly increased (Supporting Fig. S1 ), but did not meet levels of significance. In contrast to EGF, however, HGF was highly correlated with various markers of liver damage, including transaminase levels, M65, M30, and LS (not shown). In summary, levels of the apoptotic marker, M30, significantly increased during alcohol detoxification, in contrast to all other markers of liver injury. Notably, M30 levels were highly associated with cytokines and growth factors important for liver regeneration.
M30 AND M65 SERUM LEVELS PREDICT NON-HCC LIVER-RELATED DEATH IN ALD
In the prospective cohort of patients with alcoholic cirrhosis (AC), 55 of 230 patients developed HCC during a median follow-up of 67.2 months. Neither Table 4S displays baseline characteristics and outcome of the remaining 175 patients according to both M65 and M30 serum levels. Median M65 and M30 levels were 650 and 255 U/L, respectively. As compared to the German cohort, these patients were significantly older (62.7 vs. 50.3; P < 0.01). As a consequence, diabetes was more prevalent (0.3 vs. 0.1; P < 0.01), a higher BMI (27.7 vs. 25.4 kg/m 2 ; P < 0.01), lower platelet count (133 vs. 208/nL), lower albumin level (5.7 vs. 3.6 g/dL), a higher bilirubin (2.8 vs. 1.3 mg/dL), and more ascites (0.37 vs. 0.05) were recorded, whereas levels for AST, ALT, gammaglutamyl-transferase (GGT), and ferritin did not significantly differ. Notably, levels of M30 and M65 were lower compared to the German cohort (307 vs. 702 U/ L and 730 vs. 1,610 U/L, respectively). However, as shown in Fig. 4 , each of the serum markers was associated with non-HCC liver-related death: Patients with M65 levels >650 U/L or M30 >255 U/L had a higher risk of death (37.5% vs. 21.1%, P 5 0.01 and 39.5% vs. 19.1%, P 5 0.003, respectively). This finding was confirmed by the Kaplan-Meier method when taking into account the incidence of death over time (Fig.  3A-C) . Patients with both high M65 and M30 serum levels at baseline had a higher risk of non-HCC liverrelated death during follow-up (Supporting Table S4 ; Fig. 4C ). In univariate analysis (Table 3) , the following features were associated with a higher risk of liver- related death: high Child-Pugh score (P < 0.001) and the combination of high M30 and M65 serum levels (P 5 0.01) and lower platelet count (P 5 0.1). The high M30/M65 phenotype remained an independent risk factor for non-HCC liver-related death according to multivariable analyses (HR 5 1.9 [1.1-3.3]; P 5 0.02), along with higher Child-Pugh score (HR 5 1.3 [1.2-1.4]; P < 0.001; see Table 3 ).
Discussion
We here report on a large cohort of ALD patients in which M30 and M65 were evaluated as serum markers and correlated with liver histology and outcome. Both biomarkers correlate best with histological ballooning and hepatocellular apoptosis. In this cohort, M65 and M30 serum levels were more robustly associated with hepatocellular ballooning compared to transaminase levels. Notably, M30 serum levels even increased significantly during alcohol withdrawal, which could be explained by apoptotic cell death of sublethally damaged (e.g., ballooned) hepatocytes during detoxification. Although M30/M65 levels were slightly higher in ALD, a comparative analysis with a sex-, age-, and fibrosis-stage-matched NASH cohort did not show significant differences, indicating that both biomarkers do not allow for the discrimination of ALD and NAFLD. Finally, the combination of M30 and M65 serum levels predicted non-HCC liver-related mortality and may thus be candidate markers that could be used for the development of future scoring systems.
Both, for ALD and NAFLD, sensitive and predictive markers of disease activity are urgently needed. The introduction of noninvasive elastographical techniques has certainly improved fibrosis assessment, but monitoring of disease activity is still insufficiently solved. Our findings herein indicate that M65 and M30 predict liver damage, such as ballooning or inflammation, better than serum transaminase levels. Moreover, they are primarily associated with liver damage whereas their association with fibrosis is significantly weaker. Thus, earlier reported associations of M30 and M65 with fibrosis stages are most likely related to inflammation. In our opinion, both markers should therefore ideally be used as markers of liver damage. In addition, a recent study had reported a loss of K18 during severe ALD and NAFLD, which initially suggested to us a potentially negative association between serum K18 (M30) and hepatic expression of K18. (35) However, we found no such inverse correlation. Rather, serum M30 levels correlated highly significantly with hepatic M30 staining. Moreover, both markers were excellently correlated with histological markers and signs of apoptosis. In our opinion, serum M30 could ideally be used to noninvasively monitor apoptotic activity.
Are there any differences between M65 and M30 in relation to other parameters and histology? To our surprise, both M30 and M65 show a rather similar correlation pattern, although M30 detects the caspasemediated K18 cleavage. In general, M65 was more robustly associated with elevated serum transaminases, whereas M30 correlated slightly better with steatosis and MDB. We further think that our findings on ALD patients are also highly relevant for patients with NAFLD. In our comparative analysis of 30 age-, sex-, and fibrosis-stage-matched NAFLD and ALD patients, we could not identify significant differences with regard to M30 and M65 levels. However, M30 and M65 serum levels tend to be higher in ALD, compared to NAFLD, patients. We therefore conclude that major findings obtained on ALD may also be highly valid for NAFLD patients.
For these reasons, we believe that our interventional study on ALD patients undergoing alcohol detoxification is also highly relevant for NAFLD patients. The unexpected, but highly significant, increase of M30 upon alcohol withdrawal suggests more-specific insights into the role of apoptosis in ALD. It may have several speculative explanations, but certainly warrants further investigation given the high mortality of severe clinical AH where apoptosis has been suggested to play a role. (3, 39, 45) One explanation could be that the sudden absence of alcohol during alcohol withdrawal may unchain potentially alcohol-mediated blockage of apoptotic pathways. Thus, during detoxification, uncontrolled necrotic activity will rapidly decrease while the physiological cellular activity of apoptosis will increase and ultimately cause the controlled recycling of cellular debris. The observed increase of growth factors, such as EGF and HGF, would be in line with resumed liver regeneration after alcohol withdrawal. (43) Whether a dysregulation of this apoptotic process, for example, during uncontrolled high apoptotic activity, could be harmful for some patients and may even contribute to AH remains open, but could be an attractive novel target to study in the future. There is increasing evidence that activated caspases, in addition to their function in cell death, participate in nonapoptotic processes such as cell proliferation and differentiation. (46) Furthermore, activated caspases also play a role in liver regeneration. For instance, activated caspase-8 can induce nuclear factor kappa B (NF-jB) and its target gene, IL-6, which are important for liver regeneration and restoration of metabolic function. (43, 47) It has been recently demonstrated that patients with spontaneous recovery from ALF show higher levels of M30, TNFalpha (an important regulator of NF-jB), and IL-6 compared to patients without spontaneous recovery. (48) In contrast, patients who failed to spontaneously recover from ALF showed higher M65 levels. In our study, the decrease of M65 levels following alcohol withdrawal might therefore represent amelioration of liver injury, whereas the increase of M30 levels might, at least partially, mirror liver regeneration. The strong association of M30 with levels of IL-6, TNFalpha, and HGF and the increase of EGF during alcohol withdrawal further underline an important paralleled role of liver regeneration. Another explanation could be that the loss of toxicity during alcohol detoxification activates the physiological process of apoptosis in terms of recycling. However, dysregulation of this process, for example, by uncontrolled high apoptotic activity, could be harmful for the patients. Moreover, the newly emerging concept of autophagy may also be involved and strongly interact with apoptosis and liver regeneration. (8, 49) Notably, both M30 and M65 serum levels were associated with non-HCC liver-related death, but not HCC-related death. Patients with M65 levels >650 U/L or M30 >255 U/L had a higher probability of death (37.5% vs. 21.1%, P 5 0.01 and 39.5% vs. 19.1%, P 5 0.003, respectively).
It also remains open whether this finding on our large survival cohort is related to apoptosis or dysregulation of apoptosis in patients with ALD. It is especially notable that we did not observe any differences with regard to HCC-related death given that apoptosis is a fundamental process of tumor elimination and tumors have developed apoptosis-escaping strategies. (50) However, the higher incidence of non-HCC liver-related death in the group with elevated M30 and M65 levels seems to suggest a role of apoptosis dysregulation in the survival of ALD patients.
Taken together, our data show that the K18-associated serum markers, M30 and M65, are associated with histological ballooning and apoptosis, and their sensitivity to detect liver injury is higher as compared to conventional liver function tests. The surprising finding of M30 elevation after alcohol detoxification and their independent prediction of non-HCC liver-related death underlines the importance of apoptosis dysregulation in patients with ALD and may have novel implications for the pathophysiology of the rare, but clinical, severe AH.
